Aster DM Healthcare (ASTERDM) Stock Overview
Provides healthcare services in India. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 5/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
ASTERDM Community Fair Values
Create NarrativeSee what 17 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Aster DM Healthcare Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹769.05 |
| 52 Week High | ₹836.50 |
| 52 Week Low | ₹519.10 |
| Beta | -0.032 |
| 1 Month Change | 3.75% |
| 3 Month Change | 15.13% |
| 1 Year Change | 30.75% |
| 3 Year Change | 174.46% |
| 5 Year Change | 397.12% |
| Change since IPO | 323.60% |
Recent News & Updates
Narrative Update • Jun 22
ASTERDM: Fair Outlook As Kerala Labor Risks Balance Capacity Expansion
Analysts have kept their fair value estimate for Aster DM Healthcare steady at ₹795.27, citing updated assumptions around higher revenue growth, stronger profit margins, and a lower future P/E multiple reflected in recent Street research. What’s in the News for Aster DM Healthcare Aster DM Healthcare has scheduled a board meeting on April 30, 2026 to consider and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.
Narrative Update • Jun 05
ASTERDM: Expanded Women And Children Capacity And Dividend Will Drive Future Upside
Analysts have nudged their fair value estimate for Aster DM Healthcare higher from about ₹839.55 to roughly ₹884.24. They point to updated assumptions on growth, margins and a higher future P/E multiple following recent bullish Street research coverage.Narrative Update • May 20
ASTERDM: Fair Outlook As Kerala Strike Risks Offset Expansion Plans
Analysts have lifted their fair value estimate for Aster DM Healthcare from ₹700.67 to ₹795.27, reflecting updated assumptions on future revenue growth, profit margins and P/E multiples following recent supportive research commentary. Analyst Commentary Bullish Takeaways Bullish analysts see the revised fair value of ₹795.27 as supported by their updated assumptions on revenue growth, profit margins and the P/E they are willing to apply to the stock.Analysis Article • May 18
Here's Why We Think Aster DM Healthcare (NSE:ASTERDM) Is Well Worth Watching
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Recent updates
Narrative Update • Jun 22
ASTERDM: Fair Outlook As Kerala Labor Risks Balance Capacity Expansion
Analysts have kept their fair value estimate for Aster DM Healthcare steady at ₹795.27, citing updated assumptions around higher revenue growth, stronger profit margins, and a lower future P/E multiple reflected in recent Street research. What’s in the News for Aster DM Healthcare Aster DM Healthcare has scheduled a board meeting on April 30, 2026 to consider and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.Narrative Update • Jun 05
ASTERDM: Expanded Women And Children Capacity And Dividend Will Drive Future Upside
Analysts have nudged their fair value estimate for Aster DM Healthcare higher from about ₹839.55 to roughly ₹884.24. They point to updated assumptions on growth, margins and a higher future P/E multiple following recent bullish Street research coverage.Narrative Update • May 20
ASTERDM: Fair Outlook As Kerala Strike Risks Offset Expansion Plans
Analysts have lifted their fair value estimate for Aster DM Healthcare from ₹700.67 to ₹795.27, reflecting updated assumptions on future revenue growth, profit margins and P/E multiples following recent supportive research commentary. Analyst Commentary Bullish Takeaways Bullish analysts see the revised fair value of ₹795.27 as supported by their updated assumptions on revenue growth, profit margins and the P/E they are willing to apply to the stock.Analysis Article • May 18
Here's Why We Think Aster DM Healthcare (NSE:ASTERDM) Is Well Worth Watching
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...
Narrative Update • Apr 29
ASTERDM: Higher Execution Risk Will Restrain Benefits From Gene Therapy Expansion
Analysts have trimmed their price target on Aster DM Healthcare from ₹700 to ₹635, reflecting updated views on future revenue growth, profit margins, and a slightly adjusted P/E framework, while taking recent Street research into account. Analyst Commentary Recent price target trimming to ₹635 signals that some bearish analysts are rechecking their assumptions on revenue growth, profit margins, and the P/E framework for Aster DM Healthcare.Narrative Update • Apr 15
ASTERDM: Higher Interim Dividend Will Support Future Upside
Analysts have nudged their price target on Aster DM Healthcare slightly higher to ₹839.55, citing updated views on revenue growth, profit margin resilience and a modestly lower future P/E multiple, supported by recent bullish Street research. Analyst Commentary Recent Street commentary around Aster DM Healthcare points to a broadly constructive tone, with bullish analysts highlighting both earnings execution and valuation support in light of the revised ₹839.55 price target.Narrative Update • Apr 01
ASTERDM: Interim Dividend And Strike Resolution Will Support Future Upside
Analysts have trimmed their price target for Aster DM Healthcare slightly to ₹839.55 from ₹844.76. This reflects updated assumptions around revenue growth, profit margins and future P/E expectations.Narrative Update • Mar 18
ASTERDM: ESOP Review And Rare Disease Care Will Shape Balanced Outlook
Analysts have trimmed their fair value estimate for Aster DM Healthcare from ₹715.67 to ₹700.67, reflecting updated assumptions that combine slightly different revenue growth expectations, a change in projected profit margins, and a revised future P/E multiple. What's in the News Board meeting scheduled for Jan 30, 2026 to consider and approve unaudited standalone and consolidated financial results for the quarter and nine months ended Dec 31, 2025, and to review a proposed Employee Stock Option Scheme 2026, subject to shareholder approval (company event filing).Narrative Update • Mar 03
ASTERDM: Gene Therapy Breakthrough And ESOP Plan Will Support Future Upside
Analysts have trimmed their price target for Aster DM Healthcare slightly from ₹860 to about ₹845, reflecting updated assumptions around revenue growth, profit margins and future P/E expectations. What's in the News A board meeting is scheduled for January 30, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (Key Developments).Narrative Update • Feb 17
ASTERDM: Upcoming ESOP Plan And Rare Disease Care Will Support Bullish Outlook
Analysts have trimmed their fair value estimate for Aster DM Healthcare from ₹759.67 to ₹715.67. They pointed to updated assumptions around revenue growth, profit margins and future P/E that they see as better reflecting the current risk profile and earnings potential.Narrative Update • Feb 03
ASTERDM: Upcoming Board Meeting And ESOP Plan Will Support Bullish Outlook
Analysts have trimmed their fair value estimate for Aster DM Healthcare from ₹777.44 to ₹759.67 as they factor in updated assumptions for revenue growth, profit margins and a higher future P/E multiple. What's in the News Board meeting scheduled for January 30, 2026, to review and approve unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (Key Developments).Narrative Update • Jan 20
ASTERDM: Gene Therapy And Medical Tourism Expansion Will Support Future Upside
Analysts have trimmed their price target on Aster DM Healthcare from ₹740 to ₹700, citing updated assumptions around slightly different revenue growth, profit margins, and future P/E expectations. What's in the News Medcare Women & Children Hospital, part of Aster DM Healthcare, administered a pioneering intrathecal gene therapy for Spinal Muscular Atrophy to a three year old international patient.Analysis Article • Jan 14
We Think Aster DM Healthcare (NSE:ASTERDM) Can Stay On Top Of Its Debt
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Narrative Update • Jan 06
ASTERDM: Rare Disease Gene Therapy Expansion Will Support Stronger Profitability Profile
Analysts have lifted their price target on Aster DM Healthcare from ₹449.63 to ₹740.00, citing updated assumptions around revenue growth, profit margin profile, and a lower future P/E multiple as key drivers of the change. What's in the News Medcare Women & Children Hospital, part of Aster DM Healthcare, has administered a pioneering intrathecal gene therapy for Spinal Muscular Atrophy to a three year old international patient from Turkey, positioning Medcare among the first private providers globally to offer this treatment to an older patient group (Key Developments).Analysis Article • Dec 27
Revenue Downgrade: Here's What Analysts Forecast For Aster DM Healthcare Limited (NSE:ASTERDM)
The latest analyst coverage could presage a bad day for Aster DM Healthcare Limited ( NSE:ASTERDM ), with the analysts...Narrative Update • Dec 23
ASTERDM: Future Board Realignment And Office Shift Are Expected To Unlock Upside
Analysts have raised their price target on Aster DM Healthcare from ₹800 to ₹860, citing sharply upgraded revenue growth expectations that more than offset a slightly higher discount rate, modestly lower margin forecasts, and a de-rated future P E multiple. What's in the News Board meeting scheduled for November 6, 2025 at 10:30 IST to review unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (company filing) Consideration of adoption of Aster DM Healthcare Limited Employee Stock Option Scheme 2025, signaling focus on long term employee incentives and retention (company filing) Proposal to approve new registered office premises in the State of Hyderabad, indicating an administrative and possible strategic shift in corporate base (company filing) Planned changes in the composition of board committees, potentially impacting oversight and governance structure (company filing) Resignation of non executive director Anoop Moopen (DIN:02301362) to be taken up in the upcoming board meeting, with implications for board continuity and succession (company filing) Valuation Changes Fair Value: increased from ₹800 to ₹860, reflecting a modest upward revision in the target price.Analysis Article • Dec 17
A Look At The Intrinsic Value Of Aster DM Healthcare Limited (NSE:ASTERDM)
Key Insights Aster DM Healthcare's estimated fair value is ₹537 based on 2 Stage Free Cash Flow to Equity With ₹606...Narrative Update • Dec 09
ASTERDM: Upcoming Board Decisions And ESOP Plan Will Drive Bullish Outlook
Analysts have maintained their price target on Aster DM Healthcare at ₹777.44 per share, reflecting continued confidence in the company’s robust revenue growth outlook, stable profit margins, and supportive future earnings multiple. What's in the News Board to meet on November 6, 2025 at 10:30 IST to review unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (company filing) Board to consider adoption of Aster DM Healthcare Limited Employee Stock Option Scheme 2025, signaling continued focus on long term employee incentives (company filing) Proposal to approve a new registered office premises in the State of Hyderabad, indicating an administrative and potential strategic relocation (company filing) Board to review changes in the composition of its committees as part of broader governance updates (company filing) Resignation of Non Executive Director Anoop Moopen (DIN:02301362) to be taken up at the meeting, which may alter board dynamics (company filing) Valuation Changes Fair Value: Unchanged at approximately ₹777.44 per share, indicating no revision to the intrinsic value estimate.Narrative Update • Nov 25
ASTERDM: Upcoming Board Review And Approved Dividend Will Drive Positive Outlook
Analysts have raised their price target for Aster DM Healthcare from ₹707 to ₹777, citing expectations of stronger revenue growth and improved profit margins in the future. What's in the News Board meeting scheduled for November 6, 2025, to review unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (Key Developments) The board will consider the adoption of the Aster DM Healthcare Limited Employee Stock Option Scheme 2025 during the upcoming meeting (Key Developments) Approval of new registered office premises in the State of Hyderabad is on the board meeting agenda (Key Developments) Changes in the composition of committees and the resignation of Non-Executive Director Mr. Anoop Moopen will be considered (Key Developments) Final dividend of INR 1 per equity share approved for the financial year ended March 31, 2025 (Key Developments) Valuation Changes Consensus Analyst Price Target has increased from ₹707.11 to ₹777.44, reflecting a positive adjustment in valuation.Analysis Article • Nov 09
Some Analysts Just Cut Their Aster DM Healthcare Limited (NSE:ASTERDM) Estimates
One thing we could say about the analysts on Aster DM Healthcare Limited ( NSE:ASTERDM ) - they aren't optimistic...Narrative Update • Nov 06
ASTERDM: Results Review And Dividend Decision Will Influence Risk Outlook
Analysts have slightly raised their fair value estimate for Aster DM Healthcare from ₹704.44 to ₹707.11. This change reflects subtle adjustments in discount rate, growth expectations, and profitability forecasts.Narrative Update • Oct 23
Analysts Raise Aster DM Healthcare Price Target as Profit Margins Improve and Valuation Increases
Narrative Update on Aster DM Healthcare Analysts have revised their price target for Aster DM Healthcare upward from ₹675 to ₹704.44, reflecting improved profit margin expectations, even as revenue growth projections have been slightly moderated. What's in the News The company approved a final dividend of INR 1 per equity share for the financial year ended March 31, 2025.Analysis Article • Oct 20
Aster DM Healthcare Limited's (NSE:ASTERDM) Popularity With Investors Is Clear
When you see that almost half of the companies in the Healthcare industry in India have price-to-sales ratios (or...Narrative Update • Oct 09
Mergers And Expansion Will Unlock India's Healthcare Potential
Analysts have raised their price target for Aster DM Healthcare from ₹659 to ₹675. They cite significantly improved revenue growth prospects, which offset reduced profit margins and a lower forecast for future price-to-earnings multiples.Analysis Article • Sep 28
Is Aster DM Healthcare (NSE:ASTERDM) Using Too Much Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analysis Article • Sep 07
Returns Are Gaining Momentum At Aster DM Healthcare (NSE:ASTERDM)
If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...Analysis Article • Aug 16
Aster DM Healthcare (NSE:ASTERDM) Has Announced That Its Dividend Will Be Reduced To ₹1.00
Aster DM Healthcare Limited ( NSE:ASTERDM ) has announced that on 4th of October, it will be paying a dividend of₹1.00...Analysis Article • Aug 02
Aster DM Healthcare's (NSE:ASTERDM) Dividend Is Being Reduced To ₹1.00
Aster DM Healthcare Limited's ( NSE:ASTERDM ) dividend is being reduced from last year's payment covering the same...Analysis Article • May 29
Aster DM Healthcare (NSE:ASTERDM) Has A Pretty Healthy Balance Sheet
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analysis Article • Apr 25
Aster DM Healthcare Limited (NSE:ASTERDM) Shares Could Be 21% Above Their Intrinsic Value Estimate
Key Insights Aster DM Healthcare's estimated fair value is ₹419 based on 2 Stage Free Cash Flow to Equity Aster DM...
New Narrative • Feb 09
Merger With QCIL Will Create One Of India's Top 3 Hospital Chains
The merger with Quality Care India Limited aims to enhance Aster DM Healthcare's market position and boost revenue through increased hospital capacity.Analysis Article • Oct 31
Aster DM Healthcare's (NSE:ASTERDM) Sluggish Earnings Might Be Just The Beginning Of Its Problems
Despite Aster DM Healthcare Limited's ( NSE:ASTERDM ) recent earnings report having lackluster headline numbers, the...Analysis Article • Oct 14
Here's What's Concerning About Aster DM Healthcare's (NSE:ASTERDM) Returns On Capital
What underlying fundamental trends can indicate that a company might be in decline? Businesses in decline often have...Analysis Article • Jul 20
Aster DM Healthcare Limited's (NSE:ASTERDM) Popularity With Investors Is Under Threat From Overpricing
There wouldn't be many who think Aster DM Healthcare Limited's ( NSE:ASTERDM ) price-to-sales (or "P/S") ratio of 4.3x...Analysis Article • Jun 23
Capital Allocation Trends At Aster DM Healthcare (NSE:ASTERDM) Aren't Ideal
What underlying fundamental trends can indicate that a company might be in decline? A business that's potentially in...Analysis Article • May 30
Aster DM Healthcare (NSE:ASTERDM) Takes On Some Risk With Its Use Of Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analysis Article • Apr 14
With Aster DM Healthcare Limited (NSE:ASTERDM) It Looks Like You'll Get What You Pay For
When close to half the companies in India have price-to-earnings ratios (or "P/E's") below 31x, you may consider Aster...Shareholder Returns
| ASTERDM | IN Healthcare | IN Market | |
|---|---|---|---|
| 7D | -5.0% | 0.9% | -0.5% |
| 1Y | 30.7% | 9.0% | -2.3% |
Return vs Industry: ASTERDM exceeded the Indian Healthcare industry which returned 10.4% over the past year.
Return vs Market: ASTERDM exceeded the Indian Market which returned -1.8% over the past year.
Price Volatility
| ASTERDM volatility | |
|---|---|
| ASTERDM Average Weekly Movement | 4.3% |
| Healthcare Industry Average Movement | 5.9% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in IN Market | 10.0% |
| 10% least volatile stocks in IN Market | 4.4% |
Stable Share Price: ASTERDM has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: ASTERDM's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | 15,334 | N. Prashanth | www.asterdmhealthcare.in |
Aster DM Healthcare Limited, together with its subsidiaries, provides healthcare services in India. It operates through Hospitals, Clinics, Wholesale Pharmacies, and Others segments. The company operates hospitals, clinic, and in-house pharmacies at the hospitals and clinics.
Aster DM Healthcare Limited Fundamentals Summary
| ASTERDM fundamental statistics | |
|---|---|
| Market cap | ₹397.46b |
| Earnings (TTM) | ₹3.88b |
| Revenue (TTM) | ₹46.43b |
102.4x
P/E Ratio8.6x
P/S RatioIs ASTERDM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ASTERDM income statement (TTM) | |
|---|---|
| Revenue | ₹46.43b |
| Cost of Revenue | ₹19.24b |
| Gross Profit | ₹27.19b |
| Other Expenses | ₹23.31b |
| Earnings | ₹3.88b |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 7.51 |
| Gross Margin | 58.55% |
| Net Profit Margin | 8.36% |
| Debt/Equity Ratio | 14.5% |
How did ASTERDM perform over the long term?
See historical performance and comparisonDividends
0.7%
Current Dividend Yield16%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/26 06:24 |
| End of Day Share Price | 2026/06/25 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2026/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Aster DM Healthcare Limited is covered by 24 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Harith Ahamed | Avendus Spark |
| null null | Axis Capital Limited |
| Kunal Randeria | Axis Capital Limited |